Research Analysts Set Expectations for ANRO Q1 Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Friday, March 21st. William Blair analyst M. Minter forecasts that the company will earn ($0.53) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $2.56 on Monday. The business has a 50 day moving average price of $3.56 and a 200 day moving average price of $5.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. The company has a market capitalization of $69.04 million and a P/E ratio of -1.01. Alto Neuroscience has a 1-year low of $2.53 and a 1-year high of $18.35.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.09.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after acquiring an additional 3,139 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares in the last quarter. Deutsche Bank AG raised its position in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock worth $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new stake in Alto Neuroscience in the 4th quarter valued at approximately $74,000. Finally, Jane Street Group LLC grew its holdings in Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after buying an additional 7,783 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.